Want to see SE:VICO full AI Analyst Report?
VICO Stock Chart & Stats
kr11.08
-kr0.08(-1.06%)
At close: 4:00 PM EST
kr11.08
-kr0.08(-1.06%)
Day’s Range― - ―
52-Week Rangekr7.66 - kr18.24
Previous CloseN/A
Volume158.42K
Average Volume (3M)520.11K
Market Cap
kr3.23B
Enterprise Valuekr2.27B
Total Cash (Recent Filing)kr1.06B
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 21, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding281,525,600
10 Day Avg. Volume692,423
30 Day Avg. Volume520,111
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio-7.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr35.50Price Target Upside220.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.71
Revenue Forecast (FY)kr883.40K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetMinimal debt and a sizable equity base materially reduce financial risk and interest burden, giving management flexibility to fund clinical programs, pursue partnerships, and withstand financing cycles without immediate solvency pressure. This durability supports program continuity over months.
Focused Clinical-stage Pipeline (AT2R, IPF)A concentrated, mechanism-driven pipeline in a high-unmet-need niche (IPF) provides a clear strategic focus. Proprietary AT2R small-molecule assets can yield durable value via clinical readouts, licensing or partnerships and align incentives for targeted resource allocation over multiple quarters.
Improving Free Cash Flow TrendAn improving free cash flow trajectory signals rising cash efficiency and potential extension of runway if sustained. Even though absolute burn remains large, a positive growth rate in FCF indicates management may be moderating spend or achieving program efficiencies that help reduce future financing frequency.
Bears Say
Very Small And Declining Revenue BaseNegligible and falling revenues leave the company reliant on external financing and clinical milestones rather than operating cash flow. Over a multi-month horizon this constrains reinvestment capacity and heightens execution risk if capital markets tighten or fundraising terms deteriorate.
Large, Persistent Cash BurnSustained negative operating and free cash flow at scale creates ongoing funding needs and increases dilution risk. Without clear near-term inflection from partnerships or clinical milestones, persistent burn can force rapid financing, constrain strategic choices, and pressure long-term program funding.
Capital Being Consumed; Negative ROEA deeply negative ROE shows shareholder capital is eroding rather than generating returns, weakening the balance sheet over time. Continued capital consumption reduces financial flexibility, increases the probability of future dilution, and undermines investor confidence absent demonstrable clinical progress.
Vicore Pharma Holding AB News
VICO FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was kr7.66 and its highest was kr18.24 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is kr3.23B.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Aug 21, 2026 which is in 34 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on May 06, 2026. The company reported -kr0.39 earnings per share for the quarter, beating the consensus estimate of -kr0.48 by kr0.09.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.45.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -kr0.39 in its last earnings report, beating expectations of -kr0.48. Following the earnings report the stock price went up 6.557%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in SE:VICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
VICO Stock 12 Month Forecast
Average Price Target
kr35.50
▲(220.40% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xspray Pharma AB
―
Cantargia AB
―